antibiotic resistance

We at ACSH are fortunate to have amongst our erudite Advisors Dr. David Shlaes, one of the world experts in the fields of both antibiotic research and FDA regulatory policies. Shlaes has been intimately involved with the FDA, which he has both criticized and worked with, trying to prevent us from entering a pre-penicillin age, when there were no effective treatments for bacterial infections.
The cranial sinuses are eight cavities within the skull that supply vocal resonance. When they become inflamed, often accompanied by facial pain, fever, and nasal congestion, the condition is called sinusitis. Sinusitis will affect one in eight American adults in their lifetime, and can be caused by an infection from a virus (most commonly), bacteria, or fungus; it can also be the result of an allergic reaction.
There is an op-ed in today s New York Times written by former Obama administration health guru Dr. Ezekiel Emanuel, which supposedly addresses the dire need for new antibiotics which is both wrong and misleading.
A new antibiotic has been discovered that has been found to treat many common bacterial infections. Incredibly, no resistance has been detected so far. The research was published this week in the journal Nature.
At ACSH, we probably spend more time debunking phony or overblown fears than anything else. Between bad science, hidden agendas, and terrible press coverage we never run out of things to do. Although most scares vaccines, minute traces of chemicals in the environment, or GM foods, for example are baseless, this does not mean that all of them are.
In the twenty years too late is better than nothing department, the antibiotic crisis is squarely in the news today after President Obama issued an executive order that will establish a new inter-agency task force for the sole purpose of developing a national strategy to combat antibiotic-resistant bacteria.
We have often written about the antibiotic crisis in which we now find ourselves. The main problem standing in the way of progress in the development of new, effective antibiotics seems to be that it s very expensive, and companies are not incentivized to invest time and money in this area. A blockbuster drug (e.g. Lipitor) has to
In a hard-hitting op-ed in today s NY Times, food writer Ruth Reichl takes the FDA to task for not taking strong action to limit or ban the use of antibiotics in food animals.
Bacterial resistance is a devastating problem. Over two-million Americans suffer from antibiotic-resistant infections every year, causing about 23,000 deaths. And the World Health Organization warns that a post-antibiotic era may be upon us, when common infections and minor injuries
If you are looking for someone who is perfectly suited to interact with, provide guidance to, or simply scream at the FDA regarding their disastrous policies for clinical trials of new antibiotics that have put all of us as risk look no further than Dr. Shlaes first Science 2.0 piece.
We at ACSH have written frequently about the misguided change in mindset by the FDA two decades ago that brought most antibiotic research to a dead stop. No one has been deeper in the FDA trenches than ACSH advisor and infectious disease expert Dr. David Shlaes. He has been blogging, advising, lobbying, begging, and doing just about everything short of pulling his hair out to convince the infectious disease division of the FDA to reverse the disastrous changes in clinical trial policy that caused almost all drug companies to abandon research in this area.
Get the latest news on the costly Hepatitis C drug, why C-sections have skyrocketed in numbers, and the real reason behind the lack of research on antibiotic research